Although EGFR/RB1/TP53 triple mutation seems to identify a group of patients at the highest risk for SCLC transformation, biomarkers to predict transformation to SCC, EMT, and LCNEC are currently lacking. The gene discussed is TP53; the disease is small cell lung carcinoma.